A double-blinded; randomized; controlled phase 2a safety; proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Principal Investigator Last Name
Awardee Organization
Awardee State
Contact PI Country
Project Detail
Funding Organization
Agency/Funding Organization
Funding Organization Country
Program Official